SUBSCRIBE
SUBSCRIBE

TG Therapeutics, Inc.

NEWS
Pharm Country
TG Therapeutics to Participate in the H.C. Wainwright Global Investment Conference Presentation available for on demand download beginning Tuesday May 24, 2022 at 7:00 AM ET
May 20, 2022
 · 
1 min read
Pharm Country
TG Therapeutics to Participate in the B. Riley Securities’ 2022 Virtual Neuro & Ophthalmology Conference
April 26, 2022
 · 
1 min read
Policy
FDA Committee Shuts Door on Single-Arm Trials for PI3K Inhibitors
April 21, 2022
 · 
4 min read
 · 
Alex Keown
Jason Armond / Los Angeles Times via Getty Images
Drug Development
FDA’s Cancer Advisory Committee to Evaluate Safety of PI3K inhibitors
April 20, 2022
 · 
5 min read
 · 
Mark Terry
Pictured: Stop sign in front of FDA headquarters/S
Drug Development
TG Therapeutics Backpedals on BLA for Lymphoma, Leukemia Treatment
April 15, 2022
 · 
3 min read
 · 
Mark Terry
Pharm Country
TG Therapeutics Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients with CLL and SLL
April 15, 2022
 · 
13 min read
Drug Development
TG Therapeutics Announces Oral Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the American Academy of Neurology Annual Meeting
April 6, 2022
 · 
7 min read
Drug Development
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the American Academy of Neurology Annual Meeting
April 4, 2022
 · 
10 min read
Drug Development
FDA Action Alert: BMS, Marinus, Merck and More
March 13, 2022
 · 
3 min read
 · 
Mark Terry
Pharm Country
TG Therapeutics Announces Scheduling of Planned Oncologic Drug Advisory Committee Meeting
March 10, 2022
 · 
14 min read
Drug Development
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the American Academy of Neurology Annual Meeting
March 4, 2022
 · 
9 min read
Pharm Country
TG Therapeutics Announces Extension of U.S. FDA BLA/sNDA PDUFA Date for Ublituximab Plus UKONIQ® (U2) to Treat Patients with CLL and SLLFDA sets updated PDUFA goal date of June 25, 2022
March 3, 2022
 · 
15 min read
Drug Development
Biopharma Takes a Decisive Position on the Russia-Ukraine Conflict
March 1, 2022
 · 
4 min read
 · 
Heather McKenzie
Business
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results Conference call to be held today, Tuesday, March 1, 2022, at 8:30 AM ET
March 1, 2022
 · 
13 min read
Pharm Country
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
February 25, 2022
 · 
9 min read
Business
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2021 Financial Results and Business UpdateConference call to be held Tuesday, March 1, 2022 at 8:30 AM ET
February 24, 2022
 · 
1 min read
Load More
AWARDS
  • 2026 - Best Places to Work - Badge (1).png
JOBS